Novo Scores Phase III Insulin Win, Potentially Strengthening Market Position

Denmark-based Novo Nordisk announced results from two Phase IIIa comparative trials evaluating its once-weekly insulin icodec. The results showed that insulin icodec is as non-inferior to Sanofi’s insulin glargine, Lantus, potentially bringing another major competitor into the insulin space.